Marinella Roberti

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Stefania Girotto · 7 shared papers, 2019–2026 · strength 1.06
   • Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
2. Andrea Cavalli · 7 shared papers, 2019–2026 · strength 1.06
   • Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
3. Greta Bagnolini · 6 shared papers, 2019–2026 · strength 0.94
   • Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
4. Mirco Masi · 3 shared papers, 2024–2026 · strength 0.60
   • Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
5. Naomi Walsh · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
6. Samuel Harry Myers · 3 shared papers, 2024–2025 · strength 0.52
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗
7. Fabrizio Schipani · 4 shared papers, 2019–2024 · strength 0.46
   • Paper An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic let… DOI 10.1016/j.ejmech.2023.116114↗
   • Paper RAD51 nuclear recruitment and inhibition towards innovative strategies against pancreatic cancer DOI 10.1101/2021.02.03.429564↗
   • Paper Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homolog… DOI 10.1021/acs.jmedchem.9b01526↗
8. Giovanni Ferrandi · 2 shared papers, 2025–2026 · strength 0.44
   • Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711↗
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
9. Shannon R. Nelson · 2 shared papers, 2024–2025 · strength 0.35
   • Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3↗
   • Paper Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthe… DOI 10.21203/rs.3.rs-4031427/v1↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.